SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

DRTS

Alpha Tau Medical Ltd.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

The EPS beat reflects cost management or lower-than-expected losses, but with near-zero revenue, fundamentals remain pre-commercial. The ASCO abstract acceptance is a credibility milestone that may boost investor sentiment ahead of clinical trial updates. Monitor enrollment progress in the U.S. IMPACT trial and any future revenue inflection as key catalysts.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$7.91
T+0 close · Apr 27, 2026 · via day close
Latest settled
+64.48%
T+60 · $13.01
Vs SPY
+59.70%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 27 $7.91entry
  2. T+1 · 7mo ago −7.71%α −7.23% · $7.30
  3. T+5 · 7mo ago −4.80%α −5.20% · $7.53
  4. T+20 · 6mo ago +31.10%α +26.14% · $10.37
  5. T+60 · 4mo ago +64.48%α +59.70% · $13.01
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau Medical announced abstract acceptance of pooled clinical data from 58 pancreatic cancer patients at the 2026 ASCO Annual Meeting, a prestigious oncology conference. The company also reported Q4 2025 earnings with an EPS of $-0.08, beating consensus by 35.3%, though revenue was minimal at $66K. The ASCO recognition signals growing scientific validation for its Alpha DaRT therapy.

Key Financial Metrics

EPS
−$0.08
est −$0.12 · +35.3%
Revenue
$66.0K
est $66.0K · 0.0%
Rating
beat

Key Facts

  • Q4 2025 EPS: $-0.08 (consensus: $-0.12), representing a 35.3% beat
  • Revenue: $66K (in line with estimates)
  • Abstract on Alpha DaRT for pancreatic cancer accepted at ASCO 2026 Annual Meeting
  • Data pooled from 58 patients across three clinical studies in Canada and Israel
  • ASCO is the world's largest and most prestigious oncology conference
  • Forward-looking commentary on U.S. IMPACT and French ACAPELLA trials ongoing

Financial Impact

EPS loss narrowed by $0.04 YoY (from $-0.14 to $-0.08), revenue remains negligible at $66K

epsrevenue

Risk Factors

  • Company remains pre-revenue with significant ongoing losses
  • Clinical data is preliminary and may not predict final trial outcomes
  • Heavy reliance on successful regulatory approval and future funding

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
80% bullish (10 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3281701

US Market Status

Market Closed · Opens in 9h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026